Essential Tremor: Medical Management
Despite being the most common pathological tremor, essential tremor (ET) has a remarkably limited pharmacological armamentarium. Propranolol and primidone — both introduced for other indications decades ago — remain the only Level A (established effective) medications. Approximately 50% of patients achieve meaningful tremor reduction with first-line therapy, but response is often partial and head/voice tremor remains particularly resistant to oral medications. Two-thirds of patients report tremor-related disability, and 15–25% take early retirement. The 2023 NEJM trial of botulinum toxin for head tremor (Marques et al.) and the first-ever positive Phase 3 program for an ET drug (ulixacaltamide, October 2025) represent the most significant treatment advances in decades.
Bottom Line
- First-line (Level A): Propranolol 120–240 mg/day (~50% tremor reduction) and primidone 250–750 mg/day (comparable efficacy); combination provides incremental benefit
- Second-line (Level B): Topiramate >200 mg/day (most effective second-line, but 30–54% dropout), gabapentin 1200–3600 mg/day, sotalol, atenolol
- Botulinum toxin: Now supported by Class I evidence for head tremor (Marques 2023 NEJM: 31% vs. 9% improved, P=0.009); customized kinematic-guided hand injections (Jog 2020) minimize weakness
- Noninvasive stimulation: TAPS/Cala device (FDA 510(k) 2021, CMS coverage 2022) — wrist-worn 40-min stimulation sessions with ~1-hour post-treatment benefit
- Novel agents: Ulixacaltamide (T-type Ca2+ channel blocker) achieved the FIRST positive Phase 3 in ET history (October 2025); NDA filing planned early 2026. Suvecaltamide FAILED Phase 2 (July 2024)
- Counseling: ET is associated with cognitive decline (27% MCI, 12%/year MCI→dementia), depression, social withdrawal, and falls — address proactively
First-Line Medications
Propranolol
| Parameter | Details |
|---|---|
| Evidence level | AAN Level A (established as effective); MDS 2019: Efficacious (clinically useful) |
| Mechanism | Nonselective beta-adrenergic blocker; tremor reduction primarily via peripheral beta-2 receptor blockade at skeletal muscle spindles (supported by sotalol data showing efficacy despite poor CNS penetration) |
| Dosing | Start 10 mg TID; titrate to 120–240 mg/day in divided doses (some patients tolerate up to 320 mg/day) |
| Efficacy | ~50% tremor amplitude reduction; sustained limb tremor benefit without tolerance at 12 months |
| Long-acting | Propranolol LA (once daily) is equivalent in efficacy to immediate-release; preferred for adherence |
| Head tremor | Level C evidence only (weaker than for limb tremor) |
Contraindications: Asthma/severe COPD (beta-2 bronchospasm), severe heart failure, second/third-degree AV block, insulin-dependent diabetes with frequent hypoglycemia (masks symptoms), severe bradycardia. Depression is a relative contraindication (propranolol may worsen mood).
Side effects (up to 66% incidence, mostly mild; <10% dropout): Lightheadedness, hypotension, bradycardia, fatigue, exercise intolerance, erectile dysfunction, drowsiness, weight gain, cold extremities.
Primidone
| Parameter | Details |
|---|---|
| Evidence level | AAN Level A (established as effective); MDS 2019: Efficacious (clinically useful) |
| Mechanism | Barbiturate-derivative anticonvulsant; metabolized to phenobarbital (GABAergic, CYP inducer) + PEMA; anti-tremor effect appears within 60 minutes (before peak phenobarbital levels), suggesting the parent compound contributes directly |
| Dosing | Start 12.5–25 mg at bedtime; titrate extremely slowly over weeks to 250–750 mg/day in divided doses |
| Efficacy | ~50–70% responder rate; comparable to propranolol; no tolerance at 12 months; patient preference for primidone (64% vs. 36%) in one head-to-head comparison despite more initial side effects |
First-Dose Phenomenon
Up to 50% of patients experience an acute "toxic" reaction after the very first dose, even at 25 mg. Symptoms include severe sedation, nausea/vomiting, dizziness, ataxia, and confusion. In some series, 77% experienced acute symptoms. Functional tolerance develops within days. Dropout rates range from 7.5–42% due to these initial effects. Always start at the lowest possible dose at bedtime.
Drug Interactions
Phenobarbital (primidone's metabolite) is a broad-spectrum CYP inducer affecting CYP1A2, CYP2C9, CYP2C19, and CYP3A4. This has clinically significant interactions with:
- Warfarin: Increased clearance, decreased INR, reduced anticoagulant effect (warfarin resistance cases reported)
- DOACs: Sub-therapeutic anticoagulation levels (case report with apixaban requiring dose adjustment)
- Other CYP-metabolized drugs may have reduced efficacy
Propranolol + Primidone Combination
The combination (primidone 250 mg at bedtime + propranolol 80 mg TID) shows greater benefit for postural tremor than either drug alone, though the incremental improvement is modest. Some reports suggest the combination is particularly useful for head tremor. Most guidelines recommend trialing monotherapy with each agent before combining.
Second-Line Medications
| Agent | Evidence | Dosing | Key Points |
|---|---|---|---|
| Topiramate | AAN Level B; MDS: Efficacious at >200 mg/day | Start 25 mg/day; titrate by 25 mg/week to 200–400 mg/day | Most effective second-line agent; efficacy approaches first-line. 30–54% dropout from paresthesia, cognitive impairment ("brain fog"), weight loss, nephrolithiasis |
| Gabapentin | AAN Level B; MDS: Insufficient evidence | 1200–3600 mg/day (TID) | Mixed results; some studies show comparability to propranolol, others no benefit. Well tolerated (sedation, dizziness). No evidence for adjunctive use |
| Sotalol | AAN Level B; MDS: Insufficient | 75–200 mg/day BID | Nonselective beta-blocker + Class III antiarrhythmic. Water-soluble (poor CNS penetration) yet effective — supports peripheral beta-2 mechanism. Requires QT monitoring (torsades risk) |
| Atenolol | AAN Level B; MDS: Insufficient | 50–150 mg/day | Beta-1 selective (cardioselective); inferior to propranolol (37% tremor reduction); useful when propranolol contraindicated (mild asthma/COPD) |
| Alprazolam | AAN Level B; MDS: Likely efficacious | 0.75–1.5 mg/day | Improved severity in 2 studies; somnolence in 50%. Dependence, tolerance, withdrawal risk. Reserve for anxiety-exacerbated tremor |
Agents Without Established Benefit
- Pregabalin: AAN Level U; MDS: Nonefficacious. Conflicting studies — one showed worsening QoL with no tremor improvement
- Zonisamide: AAN Level U. Conflicting Class III studies
- Acetazolamide: MDS: Unlikely useful (safety concerns)
- Clonazepam: AAN Level C. Effective but limited by sedation, abuse potential, and withdrawal concerns
Botulinum Toxin
Head Tremor: Marques et al. 2023 (NEJM)
First Large RCT for Head Tremor
Design: Multicenter, double-blind, randomized, placebo-controlled; 117 patients with isolated or essential head tremor
Intervention: AbobotulinumtoxinA injected under EMG guidance into bilateral splenius capitis muscles; two injection cycles (day 0 and week 12)
Primary endpoint: ≥2-point improvement on CGI at week 18
Result: 31% vs. 9% improved (relative risk 3.37; 95% CI 1.35–8.42; P = 0.009)
Adverse events: Occurred in ~50% — head/neck pain, posterior cervical weakness, dysphagia
Published in the New England Journal of Medicine, November 9, 2023. This filled a major evidence gap: prior to this trial, the MDS 2019 review found insufficient evidence for ANY head tremor intervention.
Hand Tremor: Customized Kinematic-Guided Injections
Early trials (1990s) used fixed, high-dose protocols (50–100 IU onabotulinumtoxinA) that produced dose-dependent hand weakness (30% at 50 IU, 69% at 100 IU) without improving functional outcomes.
Jog et al. 2020 (Toxins): Randomized, double-blind, placebo-controlled crossover trial in 33 ET patients. Customized incobotulinumtoxinA (80–120 units) injected into 8–14 hand/forearm muscles based on tremor kinematic analytics:
- FTM motor performance: significantly improved at week 4 (P=0.003) and week 8 (P=0.031)
- Accelerometric tremor amplitude: decreased at week 4 (P=0.004) and week 8 (P<0.001)
- Persistent tremor reduction up to 24 weeks
- Only slight, transient reduction in grip strength (favorable tolerability)
Voice Tremor
- Botulinum toxin injection into thyroarytenoid muscles is the primary interventional treatment; 50–75% response rate
- Requires collaboration with otolaryngology; transcutaneous or flexible laryngoscopic approach under EMG guidance
- Lower doses needed compared to adductor spasmodic dysphonia
- Must distinguish from adductor spasmodic dysphonia: ET voice tremor is rhythmic across all voice tasks (including sustained vowels), while spasmodic dysphonia is not rhythmic and may not appear during singing/breathing
Noninvasive Peripheral Nerve Stimulation
TAPS (Transcutaneous Afferent Patterned Stimulation) — Cala Trio/kIQ
| Parameter | Details |
|---|---|
| Mechanism | Wrist-worn device delivers patterned electrical stimulation to median and radial nerves, calibrated to individual tremor frequency; directly modulates VIM thalamic activity via afferent pathways (confirmed by neuroimaging, 2025) |
| Protocol | 40-minute sessions; worn on more-affected hand; multiple daily sessions permitted |
| FDA clearance | 510(k) October 2021 (K203288) for action hand tremor in ET adults |
| CMS coverage | October 2022; ~$3,800 under Medicare Part B (HCPCS K1018) |
| Benefit duration | ~1 hour post-stimulation |
Evidence:
- Pahwa 2019 RCT (77 patients): Primary endpoint (TETRAS Archimedes spiral) not met; however, upper limb TETRAS scores significantly improved (P=0.017); ADL improvement 49% vs. 27% sham (P=0.001); 88% reported improvement vs. 62% sham (P=0.019). No significant adverse events
- 2023 pragmatic trial (N=310, CVS/Aetna): Adding TAPS to standard of care improved tremor power and ADL scores — the largest prospective device study in ET
- 23% improvement in tremor-related ADLs in open-label studies; 12-month data show reduced ET-related healthcare costs
TMS and tDCS
Investigational. At least 7 studies have explored repetitive TMS, theta burst stimulation, tDCS, and transcranial alternating current stimulation targeting the cerebellum and primary motor cortex. Some preliminary tremor reduction with consecutive daily sessions, but small sample sizes, heterogeneous protocols, and no sustained benefit established. Not recommended for clinical use outside research.
Novel Investigational Agents
Ulixacaltamide (Praxis Precision Medicines)
FIRST Positive Phase 3 in Essential Tremor History
Mechanism: Highly selective T-type (Cav3) calcium channel inhibitor; blocks abnormal thalamocortical oscillatory signals that generate tremor without impairing normal motor function.
Essential3 Phase 3 Program (October 2025):
- Study 1: 473 patients randomized 1:1; 12 weeks double-blind. Primary endpoint met: mean 4.3-point improvement on modified ADL-11 scale (statistically significant). ALL key secondary endpoints significant: rate of disease improvement, PGIC, CGI-S
- Study 2: 55% maintained response at week 8 vs. 33% placebo
- Safety: Well tolerated; no drug-related serious adverse events
- Regulatory: NDA meeting requested with FDA; filing planned early 2026
If approved, ulixacaltamide would be the first new ET drug in decades and the first specifically developed for this indication.
Failed Novel Agents
| Agent | Mechanism | Outcome |
|---|---|---|
| Suvecaltamide (SAGE-324) | GABA-A receptor PAM | Failed Phase 2 (July 2024); no significant tremor reduction vs. placebo |
| CX-8998 (Cavion) | T-type Ca2+ channel blocker | Failed Phase 2; improved some motor items but did not achieve primary endpoint; discontinued |
The poor success rate reflects poorly understood pathogenesis, clinical heterogeneity, high placebo response rates, and lack of validated outcome measures. Propranolol remains the only FDA-approved medication specifically for ET.
Treatment by Tremor Location
| Location | Oral Medications | Interventional Options |
|---|---|---|
| Hand tremor | Best response to propranolol/primidone; topiramate second-line | DBS (FDA 1997); focused ultrasound thalamotomy (FDA 2016); TAPS (FDA 2021); customized botulinum toxin |
| Head tremor | Propranolol (Level C only); combination propranolol + primidone may help | Botulinum toxin (Marques 2023 NEJM — now first-line interventional); DBS less reliable for head tremor |
| Voice tremor | Oral medications generally ineffective | Botulinum toxin into vocal folds (50–75% response); requires otolaryngology collaboration. DBS limited data (generally not effective for voice) |
| Jaw tremor | Limited data | Botulinum toxin into masseter/pterygoid muscles (small series) |
| Leg tremor | Rarely isolated; theoretical response to propranolol/primidone | DBS may be more effective for lower limb than medical therapy |
Treatment Algorithm
Stepwise Approach to ET Management
- Education and reassurance: Assess functional impact; not all tremor requires treatment
- Address modifiable exacerbants: Caffeine, anxiety, offending medications, thyroid dysfunction
- First-line monotherapy: Propranolol (if no asthma/heart failure/bradycardia) OR primidone (if beta-blocker contraindicated)
- Propranolol: start 10 mg TID, titrate to 120–240 mg/day
- Primidone: start 12.5–25 mg at bedtime, titrate to 250–750 mg/day
- Switch or combine: If monotherapy insufficient, try the other first-line agent; if both partially effective, combine
- Second-line: Topiramate (>200 mg/day), gabapentin, or alprazolam (anxiety-predominant)
- Botulinum toxin: Head tremor (abobotulinumtoxinA, EMG-guided bilateral splenius capitis); hand tremor (customized kinematic-guided); voice tremor (thyroarytenoid injection)
- Device therapy: TAPS/Cala (mild–moderate hand tremor, patient preference for non-pharmacological); DBS or focused ultrasound (medication-refractory, disabling)
Counseling and Quality of Life
Functional Disability
- 15–25% take early retirement or require occupation changes due to tremor
- Approximately a quarter of early-onset ET patients require career changes
- Handwriting impairment affects professional functioning across many occupations
- Face, head, and chin tremor are perceived as particularly stigmatizing
- Emotional distress amplifies tremor, creating a vicious cycle in social situations
Cognitive Impairment
ET and Cognitive Decline
Growing evidence links ET — particularly elderly-onset (>65 years) — to increased risk of cognitive impairment and dementia:
- Cumulative MCI prevalence: ~27% (vs. 14.5% general population)
- ~4% per year of cognitively normal ET patients develop MCI
- ~12% per year of ET patients with MCI progress to dementia
- ET patients develop dementia at 3× the rate of the general population (UT Southwestern, 2024)
- Cumulative dementia prevalence in one ET cohort: ~19%
- Cognitive deficits include attention, verbal memory, language, and frontal executive dysfunction
Mood Disorders
Depression and anxiety are significantly more prevalent in ET than in age-matched controls. Propranolol (a first-line ET medication) can itself worsen depression — an important consideration when selecting therapy. Social isolation from embarrassment compounds mood dysfunction.
Fall Risk
Gait and balance abnormalities (mild cerebellar ataxic component) are increasingly recognized. Tandem gait difficulty is common even in mild ET. Primidone and benzodiazepines can exacerbate ataxia and increase fall risk. Cognitive impairment further compounds fall risk in older patients.
Adaptive Strategies and Devices
- Weighted utensils: Add stability through increased mass, reducing functional tremor amplitude at the utensil tip
- Electronic stabilizing utensils (Liftware Steady): Sensors and actuators move the spoon/fork opposite to tremor direction; preferred by patients in comparative studies
- Other adaptive devices: Non-spill cups, button hooks, rocker knives, electric toothbrushes, voice-to-text software, slip-resistant placemats
- Occupational therapy: Task-specific training, compensatory strategies, environmental modifications; 28.6% of ET patients in one survey requested OT/PT referral
- Physical therapy: Balance training, gait assessment, fall prevention strategies
Key References
- Zesiewicz TA, Elble RJ, Louis ED, et al. Evidence-based guideline update: treatment of essential tremor. Neurology. 2011;77(19):1752–1755. (AAN Guideline, reaffirmed 2025)
- Ferreira JJ, Mestre TA, Lyons KE, et al. MDS evidence-based review of treatments for essential tremor. Mov Disord. 2019;34(7):950–958.
- Marques RE, Duarte GS, Rodrigues FB, et al. Botulinum toxin for isolated or essential head tremor. N Engl J Med. 2023;389:1753–1765.
- Jog M, Lee J, Schwalb J, et al. Customized incobotulinumtoxinA for essential tremor. Toxins. 2020;12(12):807.
- Pahwa R, Dhall R, Ostrem J, et al. An acute randomized controlled trial of noninvasive peripheral nerve stimulation in essential tremor. Neuromodulation. 2019;22(5):537–545.
- Praxis Precision Medicines. Phase 3 Essential3 program topline results. Press release, October 16, 2025.
- Louis ED, Benito-León J, Ottman R, et al. A population-based study of mortality in essential tremor. Neurology. 2007;69(21):1982–1989.
- Hopfner F, Deuschl G. Managing essential tremor. Neurotherapeutics. 2020;17(4):1603–1621.